13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002026172
Total reported value
$791.3M
$791.3M
72 檔
23.0%
During the Q1 2025 filing period, Diadema Partners LP (CIK: 0002026172) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $791.3M across 72 reported positions.
During Q1 2025, Diadema Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | Stock-Healthcare | 12.63% | +0.48% | NEW | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 10.77% | +0.58% | — | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 9.87% | — | +54.80% | |
| 4 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 8.25% | — | — | |
| 5 | PFE | Pfizer Inc | Stock-Healthcare | 5.95% | — | — | |
| 6 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 5.67% | +1.11% | — | |
| 7 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 5.12% | -1.76% | EXIT | |
| 8 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 4.66% | +0.51% | — | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.33% | — | — | |
| 10 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.27% | -0.13% | EXIT | |
| 11 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 2.14% | -0.64% | -16.11% | |
| 12 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.87% | — | +1708.39% | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.80% | — | — | |
| 14 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.62% | -3.19% | EXIT | |
| 15 | PCVX | Vaxcyte Inc | Stock-Other | 1.42% | +0.31% | +1339.85% | |
| 16 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.19% | -1.08% | EXIT | |
| 17 | MRNA | Moderna Inc | Stock-Healthcare | 1.13% | -0.50% | — | |
| 18 | ANAB | Anaptysbio Inc | Stock-Other | 1.04% | — | -32.03% | |
| 19 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.99% | -0.86% | EXIT | |
| 20 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.98% | +0.84% | — | |
| 21 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.97% | +3.36% | — | |
| 22 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.96% | — | +132.80% | |
| 23 | COGT | Cogent Biosciences Inc | Stock-Other | 0.93% | +0.30% | +559.57% | |
| 24 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.92% | — | +17.35% | |
| 25 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.75% | +0.03% | — | |
| 26 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.72% | — | — | |
| 27 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.69% | — | -33.33% | |
| 28 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 29 | MNKD | Mannkind CORP | Stock-Other | 0.68% | -0.07% | — | |
| 30 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.62% | — | +24.41% | |
| 31 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.57% | +0.23% | NEW | |
| 32 | KROS | Keros Therapeutics Inc | Stock-Other | 0.57% | — | -12.73% | |
| 33 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.56% | +0.26% | +7125.90% | |
| 34 | ZYME | Zymeworks Inc | Stock-Other | 0.56% | -0.14% | — | |
| 35 | ALT | Altimmune Inc | Stock-Other | 0.55% | — | +109.40% | |
| 36 | QURE | uniQure N.V. | Stock-Other | 0.53% | +1.50% | +90.60% | |
| 37 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.49% | — | -39.76% | |
| 38 | ETNBGBP | 89bio Inc | Stock-Other | 0.44% | — | — | |
| 39 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.38% | +0.55% | NEW | |
| 40 | SG7 | Sage Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 41 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.37% | — | — | |
| 42 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.37% | -0.01% | +27.89% | |
| 43 | ASND | Ascendis Pharma A/S | Stock-Other | 0.34% | — | -67.08% | |
| 44 | GOSS | Gossamer Bio Inc | Stock-Other | 0.31% | — | +130.45% | |
| 45 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.30% | -0.04% | EXIT | |
| 46 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.28% | — | +31.40% | |
| 47 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.26% | — | +31.44% | |
| 48 | PCRX | Pacira Biosciences Inc | Stock-Other | 0.25% | — | — | |
| 49 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.22% | -0.04% | +52.44% | |
| 50 | CLYM | Climb Bio Inc | Stock-Other | 0.21% | -0.33% | EXIT |
According to official SEC Form 13F filings, Diadema Partners LP reported a total U.S. public equity portfolio value of $791.3M across 72 disclosed positions in Q1 2025.
During Q1 2025, Diadema Partners LP's top holdings by market value included AMGN (12.6%)、LLY (10.8%)、SLNOEUR (9.9%). The largest single position, AMGN, represented 12.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AMGN, LLY, SLNOEUR) accounted for 23.0% of total reported equity market value during Q1 2025.
In Q1 2025, Diadema Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.